Cancer-Associated and Related Glycosphingolipid Antigens

Carbohydrate-Based Vaccines and Immunotherapies

Volumn , Issue , 2008, Pages 227-262

  Levery, Steven B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer associated and related glycosphingolipid antigens; Di and oligo Lex determinants in oligosaccharides and glycoconjugates generating mAbs; Lewis x pentasaccharide structure isolated and characterized as GSL

Indexed keywords

EID: 84875747863     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470473283.ch8     Document Type: Chapter

References (195)

1. Hakomori S (1986) Tumor-associated glycolipid antigens, their metabolism and organization. Chem. Phys. Lipids 42:209-233.
2. Hakomori S (1996) Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56:5309-5318.
3. Hakomori S (1998) Cancer-associated glycosphingolipid antigens: Their structure, organization, and function. Acta Anat. 161:79-90.
4. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 73:42-49.
5. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int. J. Cancer 73:50-56.
6. Hakomori S (2000) Traveling for the glycosphingolipid path. Glycoconj. J. 17:627-647.
7. Hakomori S (1999) Antigen structure and genetic basis of histo-blood groups A, B and O: Their changes associated with human cancer. Biochim. Biophys. Acta 1473:247-266.
8. Holmes EH, Hakomori S, Ostrander GK (1987) Synthesis of type 1 and 2 lacto series glycolipid antigens in human colonic adenocarcinoma and derived cell lines is due to activation of a normally unexpressed β1→3N-acetylglucosaminyltransferase. J. Biol. Chem. 262:15649-15658.
9. Hakomori S, Nudelman E, Levery SB, Patterson CM (1983) Human cancer-associated gangliosides defined by a monoclonal antibody (IB9) directed to sialosylα2→6galactosyl residue: A preliminary note. Biochem. Biophys. Res. Commun. 113:791-798.
10. Hakomori S, Patterson CM, Nudelman E, Sekiguchi K (1983) A monoclonal antibody directed to N-acetylneuraminosyl-α2,6-galactosyl residue in gangliosides and glycoproteins. J. Biol. Chem. 258:11819-11822.
11. Holmes EH, Hakomori S (1982) Isolation and characterization of a new fucoganglioside accumulated in precancerous rat liver and in rat hepatoma induced by N-2-acetylaminofluorene. J. Biol. Chem. 257:7698-7703.
12. Gessner P, Riedl S, Quentmaier A, Kemner W (1993) Enhanced activity of CMP-NeuAc: Galβ1-4GlcNAc: α2-6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Lett. 75:143-149.
13. Dall'Olio F, Malagolini N, DiStefano G, Minni F, Marrano D, Serafini-Cessi F (1989) Increased CMP-NeuAc:Galβ1,4GlcNAc-R α2,6-sialyltransferase activity in human colorectal cancer tissues. Int. J. Cancer 44:434-439.
14. Holmes EH, Hakomori S (1983) Enzymatic basis for changes in fucoganglioside during chemical carcinogenesis. Induction of a specific α-fucosyltransferase and status of an α-galactosyltransferase in precancerous rat liver and hepatoma. J. Biol. Chem. 258:3706-3713.
15. Holmes EH, Hakomori S (1987) The chemical carcinogen-induced enzyme, GDP-fucose: GM1 α1-2 fucosyltransferase in rat liver and hepatoma: Modulation by and association with phospholipids. J. Biochem. (Tokyo) 101:1095-1105.
16. Black PH (1980) Shedding from normal and cancer-cell surfaces [editorial]. N. Engl. J. Med. 303:1415-1416.
17. Black PH (1980) Shedding from the cell surface of normal and cancer cells. Adv. Cancer Res. 32:75-199.
18. Ladisch S, Gillard B,Wong C, Ulsh L (1983) Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43:3808-3813.
19. Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C, Seeger R (1987) Shedding of GD2 ganglioside by human neuroblastoma. Int. J. Cancer 39:73-76.
20. Li RX, Ladisch S (1991) Shedding of human neuroblastoma gangliosides. Biochim. Biophys. Acta 1083:57-64.
21. Chang F, Li R, Ladisch S (1997) Shedding of gangliosides by human medulloblastoma cells. Exp. Cell Res. 234:341-346.
22. Ladisch S, Ulsh L, Gillard B, Wong C (1984) Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest. 74:2074-2081.
23. Floutsis G, Ulsh L, Ladisch S (1989) Immunosuppressive activity of human neuroblastoma tumor gangliosides. Int. J. Cancer 43:6-9.
24. Grayson G, Ladisch S (1992) Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol. 139:18-29.
25. Li R, Villacreses N, Ladisch S (1995) Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res. 55:211-214.
26. Karlsson KA, Larson G (1981) Potential use of glycosphingolipids of human meconium for blood group chemotyping of single individuals. FEBS Lett. 128:71-74.
27. Andrews PW, Goodfellow PN, Shevinsky LH, Bronson DL, Knowles BB (1982) Cellsurface antigens of a clonal human embryonal carcinoma cell line: Morphological and antigenic differentiation in culture. Int. J. Cancer 29:523-531.
28. Shevinsky LH, Knowles BB, Damjanov I, Solter D (1982) Monoclonal antibody to murine embryos defines a stage-specific embryonic antigen expressed on mouse embryos and human teratocarcinoma cells. Cell 30:697-705.
29. Kannagi R, Levery SB, Ishigami F, Hakomori S, Shevinsky LH, Knowles BB, Solter D (1983) New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J. Biol. Chem. 258:8934-8942.
30. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, Hakomori S (1984) Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J. Biol. Chem. 259:14773-14777.
31. Menard S, Tagliabue E, Canevari S, Fossati G, Colnaghi MI (1983) Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res. 43:1295-1300.
32. Canevari S, Fossati G, Balsari A, Sonnino S, Colnaghi MI (1983) Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells. Cancer Res. 43:1301-1305.
33. Holgersson J, Jovall PA, Samuelsson BE, Breimer ME (1991) Blood group type glycosphingolipids of human kidneys. Structural characterization of extended globo-series compounds. Glycoconj. J. 8:424-433.
34. Blomberg J, Breimer ME, Karlsson KA (1982) Glycosphingolipids of a green monkey kidney cell line (GMK AH-1). Evidence for a novel pentaglycosylceramide based on globotetraosylceramide. Biochim. Biophys. Acta 711:466-477.
35. Siddiqui B, Hakomori S (1971) A revised structure for the Forssman glycolipid hapten. J. Biol. Chem. 246:5766-5769.
36. Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB, Solter D (1983) Stage-specific embryonic antigens (SSEA-3 and-4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 2:2355-2361.
37. Chien JL, Hogan EL (1983) Novel pentahexosyl ganglioside of the globo series purified from chicken muscle. J. Biol. Chem. 258:10727-10730.
38. Saito S, Levery SB, Salyan ME, Goldberg RI, Hakomori S (1994) Common tetrasaccharide epitope NeuAcα2→3Galβ1→3(NeuAcα2→6)GalNAc, presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities. J. Biol. Chem. 269:5644-5652.
39. Stroud MR, Stapleton AE, Levery SB (1998) The P histo-blood group-related glycosphingolipid sialosyl galactosyl globoside as a preferred binding receptor for uropathogenic Escherichia coli: Isolation and structural characterization from human kidney. Biochemistry 37:17420-17428.
40. Satoh M, Handa K, Saito S, Tokuyama S, Ito A, Miyao N, Orikasa S, Hakomori S (1996) Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. Cancer Res. 56:1932-1938.
41. Ito A, Saito S, Masuko T, Oh-Eda M, Matsuura T, Satoh M, Nejad FM, Enomoto T, Orikasa S, Hakomori SI (2001) Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues. Glycoconj. J. 18:475-485.
42. Kundu SK, Samuelsson BE, Pascher I, Marcus DM (1983) New gangliosides from human erythrocytes. J. Biol. Chem. 258:13857-13866.
43. Dasgupta S, Chien JL, Hogan EL, van Halbeek H (1991) A disialoganglioside of the globo-series from chicken skeletal muscle. J. Lipid Res. 32:499-506.
44. Levery SB, Salyan ME, Steele SJ, Kannagi R, Dasgupta S, Chien J-L, Hogan EL, van Halbeek H, Hakomori S (1994) A revised structure for the disialosyl globo-series gangliosides of human erythrocytes and chicken skeletal muscle. Arch. Biochem. Biophys. 312:125-134.
45. Hakomori S, Zhang Y (1997) Glycosphingolipid antigens and cancer therapy. Chem. Biol. 4:97-104.
46. Ito A, Levery SB, Saito S, Satoh M, Hakomori S (2001) A novel ganglioside isolated from renal cell carcinoma. J. Biol. Chem. 276:16695-16703.
47. 4) of human adenocarcinoma and the monoclonal antibody (FH9) defining this disialosyl structure. Biochemistry 25:2859-2866.
48. Fredman P, Mansson JE, Wikstrand CJ, Vrionis FD, Rynmark BM, Bigner DD, Svennerholm L (1989) A new ganglioside of the lactotetraose series, GalNAc-3'-isoLM1, detected in human meconium. J. Biol. Chem. 264:12122-12125.
49. Portoukalian J, Zwingelstein G, Dore JF (1979) Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur. J. Biochem. 94:19-23.
50. Hamilton WB, Helling F, Lloyd KO, Livingston PO (1993) Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer 53:566-573.
51. Kawamura K, Ohyama C, Watanabe R, Satoh M, Saito S, Hoshi S, Gasa S, Orikasa S (2001) Glycolipid composition in bladder tumor: A crucial role of GM3 ganglioside in tumor invasion. Int. J. Cancer 94:343-347.
52. Nores GA, Dohi T, Taniguchi M, Hakomori S (1987) Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: Requirements for tumor-associated antigen and immunogen. J. Immunol. 139:3171-3176.
53. Otsuji E, Park YS, Tashiro K, Kojima N, Toyokuni T, Hakomori S (1995) Inhibition of B16 melanoma metastasis by administration of GM3-or Gg3-liposomes: Blocking adhesion of melanoma cells to endothelial cells (anti-adhesion theraoy) via inhibition of GM3-Gg3Cer or GM3-LacCer interaction. Int. J. Oncol. 6:319-327.
54. Estevez F, Carr A, Valiente O, Mesa C, Barroso O, Sierra GV, Fernandez LE (1999) Enhancement of the immune response to poorly immunogenic gangliosides after incorporation onto very small size proteoliposomes (VSSP). Vaccine 18:190-197.
55. Gabri MR, Ripoll GV, Alonso DF, Gomez DE (2002) Role of cel surface GM3 ganglioside and sialic acid in the anti-tumor activity of a GM3-based vaccine in the murine B16 melanoma model. J. Cancer Res. Clin. Oncol. 128:669-677.
56. Saito S, Nojiri H, Satoh M, Ito A, Ohyama C, Orikasa S (2000) Inverse relationship of expression between GM3 and globo-series ganglioside in human renal cell carcinoma. Tohoku J. Exp. Med. 190:271-278.
57. Watanabe R, Ohyama C, Aoki H, Takahashi T, Satoh M, Saito S, Hoshi S, Ishii A, Saito M, Arai Y (2002) Ganglioside GM3 overexpression induces apoptosis and reduces malignant potential in murine bladder cancer. Cancer Res. 62:3850-3854.
58. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A (1998) The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 273:15866-15871.
59. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E,Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl. Acad. Sci. U.S.A. 95:11751-11756.
60. Higashi H, Nishi Y, Fukui Y, Ikuta K, Ueda S, Kato S, Fujita M, Nakano Y, Taguchi T, Sakai S (1984) Tumor-associated expression of glycosphingolipid Hanganutziu-Deicher antigen in human cancers. Gann. 75:1025-1029.
61. Hirabayashi Y, Higashi H, Kato S, Taniguchi M, Matsumoto M (1987) Occurrence of tumor-associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas. Jpn. J. Cancer Res. 78:614-620.
62. Hirabayashi Y, Kasakura H, Matsumoto M, Higashi H, Kato S, Kasai N, Naiki M (1987) Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers. Jpn. J. Cancer Res. 78:251-260.
63. Fukui Y, Maru M, Ohkawara K, Miyake T, Osada Y,Wang DQ, Ito T, Higashi H, Naiki M, Wakamiya N (1989) Detection of glycoproteins as tumor-associated Hanganutziu-Deicher antigen in human gastric cancer cell line, NUGC4. Biochem. Biophys. Res. Commun. 160:1149-1154.
64. Miyake M, Hashimoto K, Ito M, Ogawa O, Arai E, Hitomi S, Kannagi R (1990) The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. A study with specific monoclonal antibodies. Cancer 65:499-505.
65. Kawai T, Kato A, Higashi H, Kato S, Naiki M (1991) Quantitative determination of Nglycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry. Cancer Res. 51:1242-1246.
66. Bardor M, Nguyen DH, Diaz S, Varki A (2005) Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280:4228-4237.
67. Marquina G,Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S (1996) Gangliosides expressed in human breast cancer. Cancer Res. 56:5165-5171.
68. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, Rengifo E, Perez R, Fernandez LE (2000) A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19:241-247.
69. Higashi H, Sasabe T, Fukui Y, Maru M, Kato S (1988) Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn. J. Cancer Res. 79:952-956.
70. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE (2006) Role of tumourassociated N-glycolylated variant of GM3 ganglioside in cancer progression: Effect over CD4 expression on T cells. Cancer Immunol. Immunother. 55:443-450.
71. Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J, Alvarez I, Osorio M, Velazco M, Figueroa M, Ortiz R, Escobar X, Orozco M, Cruz J, Franco S, Diaz M, Roque L, Carr A, Vazquez AM, Mateos C, Rubio MC, Perez R, Fernandez LE (2006) Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99 m)Tc. Breast Cancer Res. Treat. 96:115-121.
72. Portoukalian J, Zwingelstein G, Dore JF, Bourgoin JJ (1976) Studies of a ganglioside fraction extracted from human malignant melanoma. Biochimie 58:1285-1287.
73. Dippold WG, Knuth A, Meyer Zum Buschenfelde KH (1984) Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 44:806-810.
74. Portoukalian J, Zwingelstein G, Abdul-Malak N, Dore JF (1978) Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem. Biophys. Res. Commun. 85:916-920.
75. Bernhard H, Meyer Zum Buschenfelde KH, Dippold WG (1989) Ganglioside GD3 shedding by human malignant melanoma cells. Int. J. Cancer 44:155-160.
76. Cheresh DA, Varki AP, Varki NM, Stallcup WB, Levine J, Reisfeld RA (1984) A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J. Biol. Chem. 259:7453-7459.
77. Cheresh DA, Reisfeld RA, Varki AP (1984) O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 225:844-846.
78. Tsuchida T, Saxton RE, Morton DL, Irie RF (1987) Gangliosides of human melanoma. J. Natl. Cancer Inst. 78:45-54.
79. Sjoberg ER, Manzi AE, Khoo KH, Dell A, Varki A (1992) Structural and immunological characterization of O-acetylated GD2. Evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells. J. Biol. Chem. 267:16200-16211.
80. Ye JN, Cheung NK (1992) A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Int. J. Cancer 50:197-201.
81. Ravindranath MH, Morton DL, Irie RF (1989) An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 49:3891-3897.
82. D3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. Cancer Res. 50:1403-1410.
83. Ritter G, Ritter-Boosfeld E, Adluri R, Calves M, Ren S, Yu RK, Oettgen HF, Old LJ, Livingston PO (1995) Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int. J. Cancer 62:668-672.
84. Livingston PO (1988) Immunization with purified gangliosides. J. Cell Biochem. 12E:S-123.
85. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL (1985) Immunogenicity of melanoma-associated gangliosides in cancer patients. Int. J. Cancer 35:607-612.
86. Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol. Immunother. 45:10-19.
87. Ritter G, Boosfeld E, Calves MJ, Oettgen HF, Old LJ, Livingston PO (1990) Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. Immunobiology 182:32-43.
88. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO (2004) Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 10:4717-4723.
89. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. U.S.A. 84:2911-2915.
90. Livingston PO, Calves MJ, Natoli EJJ (1987) Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: Purified GM2 is superior to whole cells. J. Immunol. 138:1524-1529.
91. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HF, Old LJ (1989) Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res. 49:7045-7050.
92. Livingston PO,Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G (1994) Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12:1036-1044.
93. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, Marciani D (1994) Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280.
94. Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ (1995) Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc. Natl. Acad. Sci. U.S.A. 92:2805-2809.
95. Livingston PO, Zhang S, Lloyd KO (1997) Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother. 45:1-9.
96. Livingston P (1998) Ganglioside vaccines with emphasis on GM2. Semin. Oncol. 25:636-645.
97. Kundu SK, Diego I, Osovitz S, Marcus DM (1985) Glycosphingolipids of human plasma. Arch. Biochem. Biophys. 238:388-400.
98. Lin B, Kubushiro K, Akiba Y, Cui Y, Tsukazaki K, Nozawa S, Iwamori M (1997) Alteration of acidic lipids in human sera during the course of pregnancy: Characteristic increase in the concentration of cholesterol sulfate. J. Chromatogr. B Biomed. Sci. Appl. 704:99-104.
99. Sela BA, Iliopoulos D, Guerry D, Herlyn D, Koprowski H (1989) Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thin-layer chromatography and immunostaining. J. Natl. Cancer Inst. 81:1489-1492.
100. Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC (1982) Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl. Acad. Sci. U.S.A. 79:7629-7633.
101. Higashi H, Hirabayashi Y, Hirota M, Matsumoto M, Kato S (1987) Detection of ganglioside GM2 in sera and tumor tissues of hepatoma patients. Jpn. J. Cancer Res. 78:1309-1313.
102. Chang F, Li R, Noon K, Gage D, Ladisch S (1997) Human medulloblastoma gangliosides. Glycobiology 7:523-530.
103. Portoukalian J, David MJ, Gain P, Richard M (1993) Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53:948-951.
104. Wu ZL, Schwartz E, Seeger R, Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 46:440-443.
105. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S (1990) Shed tumor gangliosides and progression of human neuroblastoma. Blood 75:1564-1567.
106. Valentino LA, Ladisch S (1992) Localization of shed human tumor gangliosides: Association with serum lipoproteins. Cancer Res. 52:810-814.
107. Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM (1987) Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res. 47:4243-4247.
108. Valentino LA, Ladisch S (1994) Circulating tumor gangliosides enhance platelet activation. Blood 83:2872-2877.
109. Ladisch S, Li R, Olson E (1994) Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc. Natl. Acad. Sci. U.S.A. 91:1974-1978.
110. Valentino LA, Ladisch S (1996) Tumor gangliosides enhance alpha2 beta1 integrindependent platelet activation. Biochim. Biophys. Acta 1316:19-28.
111. Koochekpour S, Pilkington GJ (1996) Vascular and perivascular GD3 expression in human glioma. Cancer Lett. 104:97-102.
112. Koochekpour S, Merzak A, Pilkington GJ (1996) Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett. 102:209-215.
113. Baumann H, Nudelman E, Watanabe K, Hakomori S (1979) Neutral fucolipids and fucogangliosides of rat hepatoma HTC and H35 cells, rat liver, and hepatocytes. Cancer Res. 39:2637-2643.
114. Nilsson O, Månsson JE, Brezicka FT, Holmgren J, Lindholm L, Sörensen S, Yngvason F, Svennerholm L (1984) Fucosyl-GM 1: A ganglioside associated with small cell lung carcinomas. Glycoconj. J. 1:43-49.
115. M1. Cancer Res. 46:1403-1407.
116. M1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies. Cancer Res. 49:1300-1305.
117. M1) antigen in serum. Cancer Res. 51:2879-2884.
118. Pallesen T, Vangsted A, Drivsholm L, Clausen H, Zeuthen J, Wallin H (1992) Serum immunoassay of a small cell lung cancer associated ganglioside: Development of a sensitive scintillation proximity assay. Glycoconj. J. 9:331-335.
119. M1. Acta Oncol. 32:845-851.
120. M1. Cancer Detect. Prev. 18:221-229.
121. M1 in human sensory nervous tissue is a target antigen in patients with autoimmune neuropathies. J. Neurochem. 61:658-663.
122. Yuki N, Ariga T (1997) Antibodies to fucogangliosides in neurological diseases. J. Neurol. Sci. 150:81-84.
123. Livingston PO, Hood C, Krug LM,Warren N, Kris MG, Brezicka T, Ragupathi G (2005) Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol. Immunother. 54:1018-1025.
124. Smith DF, Zopf DA, Ginsburg V (1978) Fractionation of sialyl oligosaccharides of human milk by ion-exchange chromatography. Anal. Biochem. 85:602-608.
125. Fukuda MN, Bothner B, Lloyd KO, Rettig WJ, Tiller PR, Dell A (1986) Structure of glycosphingolipids isolated from human embryonal carcinoma cells. The presence of mono-and disialosyl glycolipids with blood group type 1 sequence. J. Biol. Chem. 261:5145-5153.
126. Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk M, Mitchell KF, Steplewski Z, Koprowski H (1981) A monosialoganglioside is a monoclonal antibodydefined antigen of colon carcinoma. Science 212:55-56.
127. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V (1982) A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J. Biol. Chem. 257:14365-14369.
128. Magnani JL, Smith DF, Ginsburg V (1980) Detection of gangliosides that bind toxin: Direct binding of 125 I-labeled toxin to thin-layer chromatography. Anal. Biochem. 109:399-402.
129. Young WW, Jr, MacDonald EM, Nowinski RC, Hakomori SI (1979) Production of monoclonal antibodies specific for two distinct steric portions of the glycolipid ganglio-N-triosylceramide (asialo GM2). J. Exp. Med. 150:1008-1019.
130. Brockhaus M, Magnani JL, Blaszczyk M, Steplewski Z, Koprowski H, Karlsson KA, Larson G, Ginsburg V (1981) Monoclonal antibodies directed against the human Leb blood group antigen. J. Biol. Chem. 256:13223-13225.
131. Magnani JL (2004) The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch. Biochem. Biophys. 426:122-131.
132. Steinberg W (1990) The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol. 85:350-355.
133. Perkins GL, Slater ED, Sanders GK, Prichard JG (2003) Serum tumor markers. Am. Fam. Physician. 68:1075-1082.
134. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, Jr. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24:5313-5327.
135. 4) of human colonic adenocarcinoma and the monoclonal antibody (FH7) defining this structure. J. Biol. Chem. 261:5487-5495.
136. a antigens in human colorectal and pancreatic tissues. Cancer Res. 48:3834-3842.
137. Kannagi R, Kitahara A, Itai S, Zenita K, Shigeta K, Tachikawa T, Noda A, Hirano H, Abe M, Shin S, Fukushi Y, Hakomori S, Imura H (1988) Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain. Cancer Res. 48:3856-3863.
138. Young WW, Jr., Mills SE, Lippert MC, Ahmed P, Lau SK (1988) Deletion of antigens of the Lewis a/b blood group family in human prostatic carcinoma. Am. J. Pathol. 131:578-586.
139. Yang H-J, Hakomori S (1971) A sphingolipid having a novel type of ceramide and lacto-N-fucopentaose III. J. Biol. Chem. 246:1192-1200.
140. Kobata A, Ginsburg V (1969) Oligosaccharides of human milk. II. Isolation and characterization of a new pentasaccharide, lacto-N-fucopentaose 3. J. Biol. Chem. 244:5496-5502.
141. Hakomori S, Andrews HD (1970) Sphingoglycolipids with Leb activity, and the co-presence of Lea-, Leb-glycolipids in human tumor tissue. Biochim. Biophys. Acta 202:225-228.
142. Solter D, Knowles BB (1978) Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc. Natl. Acad. Sci. U.S.A. 75:5565-5569.
143. Hakomori S, Nudelman E, Levery SB, Solter D, Knowles BB (1981) The hapten structure of a developmentally regulated glycolipid antigen (SSEA-1) isolated from human erythrocytes and adenocarcinoma: A preliminary note. Biochem. Biophys. Res. Commun. 100:1578-1586.
144. Gooi HC, Feizi T, Kapadia A, Knowles BB, Solter D, Evans MJ (1981) Stage-specific embryonic antigen involves alpha 1 goes to 3 fucosylated type 2 blood group chains. Nature 292:156-158.
145. Solter D, Knowles BB (1979) Developmental stage-specific antigens during mouse embryogenesis. Curr. Top. Dev. Biol. 13(Pt 1):139-165.
146. Knowles BB, Aden DP, Solter D (1978) Monoclonal antibody detecting a stage-specific embryonic antigen (SSEA-1) on preimplantation mouse embryos and teratocarcinoma cells. Curr. Top. Microbiol. Immunol. 81:51-53.
147. Knowles BB, Rappaport J, Solter D (1982) Murine embryonic antigen (SSEA-1) is expressed on human cells and structurally related human blood group antigen I is expressed on mouse embryos. Dev. Biol. 93:54-58.
148. Hakomori S, Nudelman E, Kannagi R, Levery SB (1982) The common structure in fucosyllactosaminolipids accumulating in human adenocarcinomas, and its possible absence in normal tissue. Biochem. Biophys. Res. Commun. 109:36-44.
149. Hakomori S, Nudelman E, Levery SB, Kannagi R (1984) Novel fucolipids accumulating in human adenocarcinoma. I. Glycolipids with di-or trifucosylated type 2 chain. J. Biol. Chem. 259:4672-4680.
150. Kannagi R, Nudelman E, Levery SB, Hakomori S (1982) A series of human erythrocyte glycosphingolipids reacting to the monoclonal antibody directed to a developmentally regulated antigen SSEA-1. J. Biol. Chem. 257:14865-14874.
151. Fukuda MN, Dell A, Oates JE, Wu P, Klock JC, Fukuda M (1985) Structures of glycosphingolipids isolated from human granulocytes. The presence of a series of linear poly-N-acetyllactosaminylceramide and its significance in glycolipids of whole blood cells. J. Biol. Chem. 260:1067-1082.
152. Symington FW, Hedges DL, Hakomori S (1985) Glycolipid antigens of human polymorphonuclear neutrophils and the inducible HL-60 myeloid leukemia line. J. Immunol. 134:2498-2506.
153. Fukushi Y, Hakomori S, Nudelman E, Cochran N (1984) Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain. J. Biol. Chem. 259:4681-4685.
154. Fukushi Y, Hakomori S, Shepard T (1984) Localization and alteration of mono-, di-, and trifucosyl a1 2 3 type 2 chain structures during human embryogenesis and in human cancer. J. Exp. Med. 160:506-520.
155. Fukushi Y, Orikasa S, Shepard T, Hakomori S (1986) Changes of Lex and dimeric Lex haptens and their sialylated antigens during development of human kidney and kidney tumors. J. Urol. 135:1048-1056.
156. Itzkowitz SH, Yuan M, Fukushi Y, Palekar A, Phelps PC, Shamsuddin AM, Trump BF, Hakomori S, Kim YS (1986) Lewisx-and sialylated Lewisx-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res. 46:2627-2632.
157. Kim YS, Itzkowitz SH, Yuan M, Chung Y, Satake K, Umeyama K, Hakomori S (1988) Lex and Ley antigen expression in human pancreatic cancer. Cancer Res. 48:475-482.
158. Nakasaki H, Mitomi T, Noto T, Ogoshi K, Hanaue H, Tanaka Y, Makuuchi H, Clausen H, Hakomori S (1989) Mosaicism in the expression of tumor-associated carbohydrate antigens in human colonic and gastric cancers. Cancer Res. 49:3662-3669.
159. Rauvala H (1976) Gangliosides of human kidney. J. Biol. Chem. 251:7517-7520.
160. Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, Paulson JC (1990) ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250:1130-1132.
161. Tiemeyer M, Swiedler SJ, Ishihara M, Moreland M, Schweingruber H, Hirtzer P, Brandley BK (1991) Carbohydrate ligands for endothelial-leukocyte adhesion molecule 1. Proc. Natl. Acad. Sci. U.S.A. 88:1138-1142.
162. Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL (1991) A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J. Biol. Chem. 266:14869-14872.
163. Takada A, Ohmori K, Takahashi N, Tsuyuoka K, Yago A, Zenita K, Hasegawa A, Kannagi R (1991) Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem. Biophys. Res. Commun. 179:713-719.
164. Paulson JC, Prieels JP, Glasgow LR, Hill RL (1978) Sialyl-and fucosyltransferases in the biosynthesis of asparaginyl-linked oligosaccharides in glycoproteins. Mutually exclusive glycosylation by beta-galactoside alpha2 goes to 6 sialyltransferase and Nacetylglucosaminide alpha1 goes to 3 fucosyltransferase. J. Biol. Chem. 253:5617-5624.
165. 6 Cer). Carbohydr. Res. 178:121-144.
166. Korekane H, Tsuji S, Noura S, Ohue M, Sasaki Y, Imaoka S, Miyamoto Y (2007) Novel fucogangliosides found in human colon adenocarcinoma tissues by means of glycomic analysis. Anal. Biochem. 364:37-50.
167. Holmes EH, Ostrander GK, Hakomori S (1985) Enzymatic basis for the accumulation of glycolipids with X and dimeric X determinants in human lung cancer cells (NCI-H69). J. Biol. Chem. 260:7619-7627.
168. 6). J. Biol. Chem. 259:10511-10517.
169. Macher BA, Buehler J, Scudder P, Knapp W, Feizi T (1988) A novel carbohydrate, differentiation antigen on fucogangliosides of human myeloid cells recognized by monoclonal antibody VIM-2. J. Biol. Chem. 263:10186-10191.
170. Nudelman ED, Levery SB, Stroud MR, Salyan ME, Abe K, Hakomori S (1988) A novel tumor-associated, developmentally regulated glycolipid antigen defined by monoclonal antibody ACFH-18. J. Biol. Chem. 263:13942-13951.
171. Stroud MR, Handa K, Ito K, Salyan ME, Fang H, Levery SB, Hakomori S, Reinhold BB, Reinhold VN (1995) Myeloglycan, a series of E-selectin-binding polylactosaminolipids found in normal human leukocytes and myelocytic leukemia HL60 cells. Biochem. Biophys. Res. Commun. 209:777-787.
172. x having tetraosyl to octaosyl core. Biochemistry 35:758-769.
173. Stroud MR, Handa K, Salyan ME, Ito K, Levery SB, Hakomori S, Reinhold BB, Reinhold VN (1996) Monosialogangliosides of human myelogenous leukemia HL60 cells and normal human leukocytes. 2. Characterization of E-selectin binding fractions, and structural requirements for physiological binding to E-selectin. Biochemistry 35:770-778.
174. Hakomori S (2003) Structure, organization, and function of glycosphingolipids in membrane. Curr. Opin. Hematol. 10:16-24.
175. x epitope as the physiological myeloid cell ligand in E-selectin-dependent adhesion: Studies under static and dynamic flow conditions. Biochemistry 36:12412-12420.
176. Abe K, McKibbin JM, Hakomori S (1983) The monoclonal antibody directed to difucosylated type 2 chain (Fuc1α→2Galβ1→ 4[Fucα1→3]GlcNAc; Y Determinant). J. Biol. Chem. 258:11793-11797.
177. Clausen H, Hakomori S (1989) ABH and related histo-blood group antigens: Immunochemical differences in carrier isotypes and their distribution. Vox Sang. 56:1-20.
178. McKibbin JM, Spencer WA, Smith EL, Mansson JE, Karlsson KA, Samuelsson BE, Li YT, Li SC (1982) Lewis blood group fucolipids and their isomers from human and canine intestine. J. Biol. Chem. 257:755-760.
179. Abe K, Hakomori S, Ohshiba S (1986) Differential expression of difucosyl type 2 chain (LeY) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas. Cancer Res. 46:2639-2644.
180. Miyake M, Zenita K, Tanaka O, Okada Y, Kannagi R (1988) Stage-specific expression of SSEA-1-related antigens in the developing lung of human embryos and its relation to the distribution of these antigens in lung cancers. Cancer Res. 48:7150-7158.
181. 1H-NMR analysis of glycolipids possessing mono-and multimeric X and Y haptens: Characterization of two novel extended Y structures from human adenocarcinoma. Carbohydr. Res. 151:311-328.
182. 6) and a possible three-dimensional epitope structure. J. Biol. Chem. 261:11254-11258.
183. Kim YS, Yuan M, Itzkowitz SH, Sun QB, Kaizu T, Palekar A, Trump BF, Hakomori S (1986) Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res. 46:5985-5992.
184. Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y, Hakomori S (1991) In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope. Cancer Res. 51:2199-2204.
185. 6) as human tumor-associated antigen. J. Biol. Chem. 266:8439-8446.
186. a as human tumor associated antigens. In Garegg PJ, Lindberg AA, Eds. Carbohydrate Antigens. American Chemical Society Monographs, Vol. 519. American Chemical Society, Washington, DC, pp. 159-175.
187. Ishizuka H, Watanabe M, Kubota T, Matsuzaki SW, Otani Y, Kitajima M (1998) Antitumor activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis. Anticancer Res. 18:2513-2518.
188. Kawano Y, Watanabe M, Kubota T, Nishibori H, Kurihara N, Teramoto T, Kitajima M (1997) A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer. Anticancer Res. 17:2449-2453.
189. 6). Eur. J. Biochem. 203:577-586.
190. Ito H, Tashiro K, Stroud MR, Orntoft TF, Meldgaard P, Singhal AK, Hakomori S (1992) Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Le(b)/Le(a) glycosphingolipid, a novel extended type 1 chain antigen. Cancer Res. 52:3739-3745.
191. y) determinants in human blood cell membranes (ghosts). Evidence that type 2 chain can elongate repetitively but type 1 chain cannot. J. Biol. Chem. 260:6410-6415.
192. Pettijohn DE, Stranahan PL, Due C, Ronne E, Sorensen HR, Olsson L (1987) Glycoproteins distinguishing non-small cell from small cell human lung carcinoma recognized by monoclonal antibody 43-9F. Cancer Res. 47:1161-1169.
193. Martensson S, Due C, Pahlsson P, Nilsson B, Eriksson H, Zopf D, Olsson L, Lundblad A (1988) A carbohydrate epitope associated with human squamous lung cancer. Cancer Res. 48:2125-2131.
194. Sabharwal H, Nilsson B, Gronberg G, Chester MA, Dakour J, Sjoblad S, Lundblad A (1988) Oligosaccharides from feces of preterm infants fed on breast milk. Arch. Biochem. Biophys. 265:390-406.
195. 4 defined by monoclonal antibody 43-9F: Enzymatic synthesis, structural characterization, and comparative reactivity with various antibodies. Biochemistry 33:10672-10680.